Worldwide prevalence of allergic ailments continues to rise, with growing sensitization rates to common allergens, particularly among children. In the U.S. alone, allergies are sixth-leading cause of chronic diseases, with an annual allergy healthcare cost of over US$ 18 billion, according to the Centers for Disease Control and Prevention (CDC). A recent study of Fact.MR foresees allergy care market to continue on its steady trajectory, to exceed revenues worth US$ 5,500 Mn in 2018

 For More Insights Into The Market, Request a Sample of this Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=2382

Global Allergy Care Market by Category

• By Allergy Type :

  • Eye Allergy
  • Skin Allergy
  • Food Allergy
  • Other Allergies (Rhinitis)

• By Product Type :

  • Nasal Spray
  • Antihistamine Medication
  • Eye Drops

• By Form :

  • Tablet/Gels/Pills
  • Sprays
  • Liquids

• By Sales Channel :

  • Drug & Pharmacies Stores
  • Modern Trade
  • Departmental Stores
  • Institutional Sales
  • Monobrand Stores
  • Online Retailers

• By Region :

  • North America
  • Latin America
  • Europe
  • East Asia
  • South Asia
  • Oceania
  • MEA

Competitive Landscape: Top Companies in Allergy Care Market

The global allergy care market is highly fragmented and competitive owing to the existence of many domestic and regional players. Various marketing strategies are adopted by key players such as mergers and acquisitions, expansions, collaborations and partnerships.

Also, new product development as a strategic approach is adopted by the leading companies to upscale their market presence among consumers. These strategies have resulted in the incorporation of advanced allergy care products.

Fact.MR has provided detailed information about price points of top manufacturers of allergy care positioned across regions, sales growth, production capacity, and speculative technological expansion in the recently published report.

For instance:

• Biologics License Application for Xolair prefilled syringes for self-injection product of Genentech, a member of Roche Group was approved by U.S. Food and Drug Administration (FDA), in 2021. The innovative product is designed for the treatment of moderate to severe allergic asthma, nasal polyps, and chronic idiopathic urticarial (CIU) as it targets and blocks IgE i.e. Immunoglobulin E.
• Glenmark Pharmaceuticals Ltd. And Hikma Pharmaceuticals entered into a licensing agreement in 2020 to commercialize nasal spray for curing allergic rhinitis in the United States.

Which is the dominant region for the Allergy Care Market?

North America allergy care market is dominant in the overall market. It contributes approximately 23.8% to the overall market share and is poised to continue on the same trajectory.

In North America, the United States is the dominant country contributing approximately 19.2% to the overall market share. According to the survey conducted by the Asthma and Allergy Foundation of America in the year 2020, concluded that more than 63% of consumers had allergies, more than 55% had asthma, and more than 65% of them had a family member with some form of allergy.

In addition to this, according to the Food Allergy Research & Education report of 2020, estimated that more than 31 million United States residents were prone to food allergies and more than 38% of children are food allergic to more than one food.

Thus, all the above-listed factors are poised to place 1.5X demand for allergy care from the North America.